Overview
Kenota spent a decade bringing a rapid allergy blood test from a Waterloo laboratory concept to US regulatory clearance. The Kenota 1 Total IgE system used a fingerstick sample, processed up to 30 cartridges, and returned a result in about 25 minutes inside an allergy clinic.
FDA records establish the technical and regulatory milestone: a substantially equivalent decision and CLIA waiver in May 2024. They do not establish commercial success. Y Combinator now marks Kenota inactive and the company domain is parked, but no shutdown announcement, buyer, date, or transaction terms were found. The outcome after clearance is unresolved.
Founding Story
Moufeed Kaddoura and Eric Blondeel founded ExVivo Labs in Kitchener-Waterloo in 2014. The company won a University of Waterloo Velocity award that year and later renamed itself Kenota. It joined YC's Summer 2016 batch.
The founders targeted a specific diagnostic delay. Allergy specialists often used a skin-prick test during a visit or sent blood to an outside laboratory. Lab results could take days or weeks, and drawing blood was especially difficult for children. Kenota aimed to put a small automated immunoassay system in the specialist's office.
Timeline
- 2014: ExVivo Labs was founded and won a $25,000 Velocity award.
- Summer 2016: The company joined YC and raised a US$2 million seed round.
- Following years: Kenota built and validated its point-of-care allergy-testing system with clinicians.
- April 2021: It announced a US$9 million Series A led by Draper Associates.
- April 2023: FDA received the Kenota 1 Total IgE 510(k) submission.
- May 31, 2024: FDA issued clearance and a CLIA waiver decision.
- June 2024: Kenota said it planned specific-allergen IgE panels.
- Current record: YC lists Kenota inactive and its domain is parked; no terminal announcement was found.
What They Built
The Kenota 1 system combined an automated instrument, disposable total-IgE cartridges, external controls, a sample-collection kit, and developing solution. An operator collected capillary blood by fingerstick and loaded the sample. The instrument dispensed 4.5 microliters onto each lateral-flow cartridge and completed the run in 25 minutes.
The cleared test measured total IgE as an aid in diagnosing IgE-mediated allergic disorders. It did not by itself identify a specific allergen. Kenota's stated next step was to submit panels for specific IgE allergens.
Market Position
Target Customers
Kenota sold to allergists and immunologists who wanted blood-test information during the visit. The patient benefit was a smaller sample and faster result; the clinic benefit was control over testing time and workflow.
Market Size
The sources reviewed establish a large allergy burden but not a defensible market size for Kenota's cleared indication. Commercial value depended on instrument placement, cartridge use, reimbursement, and adoption by specialist practices.
Competition
Kenota competed with skin-prick testing, central-laboratory blood testing, and other point-of-care diagnostic systems. Its advantage was in-office speed with minimal blood. Its burden was the combined cost of hardware, consumables, quality systems, clinical evidence, sales, and reimbursement.
Business Model
The likely model paired instrument placement or sale with recurring cartridge and control purchases. Public sources do not disclose pricing, gross margin, placements, test volumes, or reimbursement. Those missing figures prevent a reliable commercial assessment.
Investors financed a long development and regulatory path: US$2 million in 2016 and US$9 million in 2021, plus other reported rounds. The 2021 capital was explicitly intended for product completion and regulatory review.
Post-Mortem
Regulatory clearance arrived. Commercial evidence did not follow in the public record reviewed. The FDA decision confirms that the product met its reviewed standard; it does not show that clinics bought instruments, insurers paid for tests, or cartridge volume supported the company.
The parked domain and inactive YC status suggest the original business may have stopped or changed, but the mechanism is unknown. Hardware cost, assay menu breadth, reimbursement, sales cycles, and financing are plausible diagnostic-company risks. None can be claimed as Kenota's cause without evidence.
The central unresolved question is what happened between clearance and distribution. A fair retrospective must leave it open.
Key Lessons
- Design regulation early. Kenota consulted FDA before its final submission and built the product around clinic operation.
- Workflow is a clinical feature. Fingerstick collection and a 25-minute result changed when a specialist could act.
- One cleared assay is a beachhead. Total IgE created a platform entry, while specific-allergen panels were still future work.
- Clearance and adoption are separate gates. Commercial proof requires placements, reimbursement, and recurring test volume.
- Do not invent the ending. A parked domain cannot identify why a regulated company stopped communicating.